


The Blood Center  
New Orleans, Louisiana

Department Name: Medical Legal

Policy Title: **TRALI PREVENTION POLICY: PHASE I  
AND II**

Version: Date Signed  
Supersedes: 08.11.03  
Pg 1 of 1  
System: Donor Suitability  
File name: ML1P0220.doc  
Copies to:

---

Written/Revised by Ian Stephens Date 07/08/2011 Yr Review: \_\_\_\_\_ Date \_\_\_\_\_  
Approved by  Date 7/8/11 Yr Review: \_\_\_\_\_ Date \_\_\_\_\_  
Approved by \_\_\_\_\_ Date \_\_\_\_\_ Yr Review: \_\_\_\_\_ Date \_\_\_\_\_  
Removed by \_\_\_\_\_ Date \_\_\_\_\_  
Reviewed by: Richard 7-8-11

---

- I. The following is The Blood Center's Phase I policy to prevent TRALI in patients who receive FFP:
- A. Two questions have been added to The Blood Center's Donor Registration Record (DRR):  

Question 49: Female donors: Have you ever been pregnant, had a miscarriage, or had an elective abortion?

Question 50: Have you ever had a blood transfusion?
  - B. If either of the questions is answered in the affirmative, The Blood Center will not manufacture plasma for transfusion, with one exception; AB plasma. The Blood Center will manufacture Recovered Plasma for Further Manufacturing – Non Injectable.
  - C. If an apheresis donor answers either of the questions in the affirmative, apheresis staff are only able to collect a RBC and/or platelet products.
- II. The following is The Blood Center's Phase II policy to prevent TRALI in patients who receive apheresis platelets:
- A. If either of the above questions is answered in the affirmative, Donor Services staff collects a tube of blood from the donor to be sent for HLA testing.
  - B. If the donor has HLA antibodies, he or she is deferred from having apheresis platelets collected.